Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Latest Peripheral membrane proteins Stories

2012-07-08 22:21:10

PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD, Attending...

2012-06-29 02:23:55

LIVERPOOL, England and NES-ZIONA, Israel, June 29, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that PROLOR scientist Dr. Gili Hart will present data on the company's long-acting clotting factors in preclinical development for the treatment of hemophilia at the 58th Annual Meeting of the Science and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH). Dr. Hart's oral presentation will take place tomorrow, June 30, 2012,...

2012-06-27 22:26:20

Long-term aim is to develop new treatments to block the spread of damaged proteins in the brain Van Andel Institute announces that researchers at Lund University in Sweden have published a study detailing how Parkinson's disease spreads through the brain. Experiments in rat models uncover a process previously used to explain mad cow disease, in which misfolded proteins travel from sick to healthy cells. This model has never before been identified so clearly in a living organism, and the...

2012-06-27 07:05:57

Long-term aim is to develop new treatments to block the spread of damaged proteins in the brain Grand Rapids, Mich. (June 27, 2012) — Van Andel Institute announces that researchers at Lund University in Sweden have published a study detailing how Parkinson's disease spreads through the brain. Experiments in rat models uncover a process previously used to explain mad cow disease, in which misfolded proteins travel from sick to healthy cells. This model has never before been identified...

2012-06-21 21:01:16

Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites. Researchers from Cincinnati Children's Hospital Medical Center report their findings online June 21 in Chemistry & Biology. The scientists named their lead drug candidate "Rhosin" and hope future testing shows it to be promising for the treatment of various cancers or nervous system...

2012-06-21 06:24:10

CINCINNATI, June 21, 2012 /PRNewswire-USNewswire/ -- Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Researchers from Cincinnati Children's Hospital Medical Center report their findings online June 21 in Chemistry & Biology. The scientists named their lead drug...

2012-06-12 06:23:43

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified several proteins that help regulate cells´ response to light–and the development of night blindness, a rare disease that abolishes the ability to see in dim light. In the new studies, published recently in the journals Proceedings of the National Academy of Sciences (PNAS) and The Journal of Cell Biology, Scripps Florida scientists were able to show that a family of...

2012-06-08 02:23:54

KING OF PRUSSIA, Pa., June 8, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine prophylaxis...

2012-06-05 02:29:01

VIENNA, June 5, 2012 /PRNewswire/ -- The worldwide first clinical trial for the development of a Parkinson's vaccine has now been started by AFFiRiS AG. The vaccine called PD01A is directed against alpha-Synuclein, a protein considered causing the onset and progression of the disease, and is currently being tested on Parkinson's patients in a Phase I trial. The vaccine holds out the prospect to deliver a causative treatment of Parkinson's for the first time. Its potential for...

2012-06-04 19:32:43

Researchers at the University of Toronto Scarborough (UTSC) used an innovative technique to examine chemical interactions that are implicated in Parkinson's Disease. The work details how a protein called alpha-synuclein interacting with the brain chemical dopamine can lead to protein misfolding and neuronal death. Parkinson's Disease is a neurodegenerative disease which results in loss of motor control and cognitive function. Although the cause isn't known precisely, the disease...


Latest Peripheral membrane proteins Reference Libraries

Paneth Cells
2012-07-01 19:03:07

Paneth Cells are one of four principal cell types found in the epithelium of the small intestine; the other three are the goblet cell, enterocyte, and enteroendocrine cell. Paneth cells may also be found in the cecum and appendix, although sporadically. These cells are identifiable microscopically by their location just below the intestinal stem cells in the intestinal glands. and the large eosinophilic refractile granules that occupy most of their cytoplasm. These granules consist of...

More Articles (1 articles) »